Department of Neurology , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 , China.
Key Laboratory of Science & Technology of Eco-Textile, Ministry of Education, College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai 201620 , China.
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41012-41018. doi: 10.1021/acsami.8b11714. Epub 2018 Nov 20.
This study explored a new rosuvastatin calcium- and heparin-loaded poly(l-lactide- co-caprolactone) (PLCL) scaffold for covered stents for treating aneurysms. The mechanism of rosuvastatin-induced endothelialization via vascular endothelial growth factor (VEGF)-A elevation was further explored. Rosu50, Rosu75, Rosu100, and phosphate-buffered saline (PBS) nanofibrous scaffolds were fabricated by coaxial electrospinning and observed by electron microscopy. Anticoagulation and pro-endothelialization properties were tested. Sixteen rabbits were selected for an in vivo assay and underwent microsurgery to establish a carotid aneurysm model. The animals were treated with covered stents and followed for 4 months using digital subtraction angiography (DSA), electron microscopy, and histology. Rosuvastatin-treated human umbilical vein endothelial cell (HUVEC) viability, function, and VEGF-A modulation were further studied to elucidate the pro-endothelialization mechanism of rosuvastatin. Our study demonstrates that rosuvastatin and heparin can be incorporated into PLCL nanofibers via electrospinning. Rosu100 nanofiber scaffolds exhibited significant anticoagulation properties. The viability of HUVECs transferred to Rosu100 nanofiber scaffolds was increased significantly. In vivo, DSA revealed that the Rosu100 group had better outcomes than the PBS group. In addition, the Rosu100 stents induced more integrated endothelialization. Further study demonstrated that rosuvastatin promoted HUVEC viability and function in vitro. The effects of rosuvastatin may be attributed to an elevation in VEGF-A. We demonstrated that rosuvastatin- and heparin-loaded PLCL-covered stents show favorable anticoagulation and pro-endothelialization properties in vitro and in vivo in a rabbit aneurysm model. VEGF-A elevation played a crucial role in rosuvastatin-promoted endothelialization. This work provides an additional option for treating cerebral aneurysms with covered stents.
本研究探索了一种新的载瑞舒伐他汀钙和肝素的聚(L-丙交酯-共-己内酯)(PLCL)支架,用于治疗动脉瘤的覆膜支架。进一步探讨了瑞舒伐他汀通过血管内皮生长因子(VEGF)-A 升高诱导内皮化的机制。通过同轴静电纺丝制备了 Rosu50、Rosu75、Rosu100 和磷酸盐缓冲盐水(PBS)纳米纤维支架,并通过电子显微镜观察。测试了抗凝和促内皮化特性。选择 16 只兔子进行体内试验,并进行显微手术建立颈动脉动脉瘤模型。动物用覆膜支架治疗,并用数字减影血管造影(DSA)、电子显微镜和组织学随访 4 个月。进一步研究了载瑞舒伐他汀的人脐静脉内皮细胞(HUVEC)活力、功能和 VEGF-A 调节,以阐明瑞舒伐他汀的促内皮化机制。我们的研究表明,瑞舒伐他汀和肝素可以通过静电纺丝掺入 PLCL 纳米纤维中。Rosu100 纳米纤维支架表现出显著的抗凝特性。转移到 Rosu100 纳米纤维支架上的 HUVEC 活力显著增加。体内,DSA 显示 Rosu100 组的结果优于 PBS 组。此外,Rosu100 支架诱导更完整的内皮化。进一步的研究表明,瑞舒伐他汀在体外促进 HUVEC 的活力和功能。瑞舒伐他汀的作用可能归因于 VEGF-A 的升高。我们证明载瑞舒伐他汀钙和肝素的 PLCL 覆膜支架在兔动脉瘤模型中具有良好的体外和体内抗凝和促内皮化特性。VEGF-A 的升高在瑞舒伐他汀促进内皮化中起着关键作用。这项工作为用覆膜支架治疗脑动脉瘤提供了另一种选择。